Essra Ridha
Corporate Officer/Principal presso The Royal College of Physicians
Patrimonio netto: 23 504 $ in data 31/05/2024
Profilo
Essra Ridha is a Member at The Royal College of Physicians.
She previously worked as a Senior Director-Medical at Sangamo Therapeutics, Inc. from 2019 to 2021.
She then served as Vice President-Clinical Development at AVROBIO, Inc. in 2021.
Currently, she holds the position of Chief Medical Officer at AVROBIO, Inc. starting from 2021.
Dr. Ridha obtained her undergraduate degree from University College London and pursued her doctorate at UCL Medical School and Royal Free Hospital Medical School.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
0.04% | 07/03/2024 | 15 881 ( 0.04% ) | 23 504 $ | 31/05/2024 |
Posizioni attive di Essra Ridha
| Società | Posizione | Inizio |
|---|---|---|
| The Royal College of Physicians | Corporate Officer/Principal | - |
Precedenti posizioni note di Essra Ridha
| Società | Posizione | Fine |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Direttore Tecnico/Scientifico/R&S | 20/06/2024 |
| TECTONIC THERAPEUTIC, INC. | Direttore Tecnico/Scientifico/R&S | 01/07/2021 |
| SANGAMO THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/02/2021 |
Formazione di Essra Ridha
| Royal Free Hospital Medical School | Doctorate Degree |
| UCL Medical School | Doctorate Degree |
| University College London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
- Borsa valori
- Insiders
- Essra Ridha
